AI
SRPT. before/open.Sarepta Therapeutics Announces Eteplirsen Meets Primary Endpoint of Increased Novel Dystrophin and Achieves Significant Clinical Benefit on 6-Minute Walk Test After 48 Weeks of Treatment in Phase IIb Study in Duchenne Muscular Dystrophy
Eteplirsen Results in an Increase in Novel Dystrophin to 47% of Normal After 48 Weeks of Treatment; Eteplirsen 50mg/kg Weekly Demonstrates Continued Clinical Benefit of 89.4 Meters in 6-Minute Walk Test Over Placebo/Delayed Treatment Cohort; No Eteplirsen-Related Adverse Events Through Week 48
http://finance.yahoo.com/news/sarepta-therapeutics-announces-eteplirsen-meets-110000135.html
Eteplirsen Results in an Increase in Novel Dystrophin to 47% of Normal After 48 Weeks of Treatment; Eteplirsen 50mg/kg Weekly Demonstrates Continued Clinical Benefit of 89.4 Meters in 6-Minute Walk Test Over Placebo/Delayed Treatment Cohort; No Eteplirsen-Related Adverse Events Through Week 48
http://finance.yahoo.com/news/sarepta-therapeutics-announces-eteplirsen-meets-110000135.html
The Penny Ticker.
http://investorshub.advfn.com/The-Penny-Ticker-17412/
5-bagger contest on Dawgg.
http://investorshub.advfn.com/%22Dawgg%22-21519/
Discover What Traders Are Watching
Explore small cap ideas before they hit the headlines.
